Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsGold Coast Fasenra Coverage Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentGold Coast Health PlanPolicy N/A

    Fasenra (benralizumab) Coverage Criteria

    Customize your policy alerts

    Sign up for all goldcoasthealthplan policy alerts

    Know when goldcoasthealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medicare Part B coverage and prior authorization for Fasenra (benralizumab) used for severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis (EGPA), including clinical documentation, prescribing qualifications, dosing, and billing requirements.

    Policy Summary
    PayerGold Coast Health Plan
    PolicyFasenra (benralizumab) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 21, 2025
    Last ReviewAug 21, 2025
    Next Review DateN/A
    Key ActionSubmit supporting medical records, including qualifying eosinophil levels and documented ICS/LABA trial and failure, for initial severe eosinophilic asthma requests.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    150 cells/mcLMinimum eosinophil level within 6 weeks
    300 cells/mcLAlternative eosinophil threshold within 12 months
    1 yearInitial coverage duration
    2 yearsReauthorization coverage duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    J0517HCPCS billing code

    Coverage Criteria

    Initial Severe Eosinophilic Asthma

    Covered for severe eosinophilic asthma when all of the following are met:

    Initial severe eosinophilic asthma

    • ALL of the following

      • ONE qualifying eosinophil threshold

        • The eosinophil level is at least 150 cells/mcL within six weeks before the immediate start of treatment with Fasenra.>= 150 cells/mcL within 6 weeks
        • The eosinophil level is at least 300 cells/mcL during the previous 12 months.>= 300 cells/mcL in previous 12 months
      • The patient has severe eosinophilic asthma requiring Fasenra as add-on therapy.
      • Medical records supporting the request, including documentation of prior therapies and responses to treatment, are provided.
      • The patient has tried and failed one ICS/LABA inhaler drug in the past six months.One ICS/LABA inhaler drug within the past 6 months

        Failure means intolerance or inability to improve the condition on required therapy for at least four weeks.

    Initial EGPA

    Covered for EGPA when all of the following are met:

    Initial eosinophilic granulomatosis with polyangiitis

    • The patient is an adult with eosinophilic granulomatosis with polyangiitis (EGPA).Adult patient
    • Medical records supporting the request are provided.
    • The patient has non-severe EGPA, defined as absence of life- or organ-threatening manifestations.Non-severe EGPA

    Fasenra must not be used in combination with other biologic drugs. Coverage may be denied when concurrent biologic therapy is identified.

    Billing and Clinical Coding Details

    HCPCS Billing CodeHCPCSCovered
    J0517Fasenra (benralizumab) prefilled syringe
    Recent eosinophil count
    Qualifying thresholdAt least 150 cells/mcL
    TimingWithin six weeks prior to the immediate start of treatment with Fasenra
    UseOne of the qualifying eosinophil thresholds for initial severe eosinophilic asthma coverage
    Historical eosinophil count
    Qualifying thresholdAt least 300 cells/mcL
    TimingDuring the previous 12 months
    Use

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Authorization and Reauthorization

    Prior authorization is required for initial treatment and reauthorization of Fasenra. Coverage criteria are indication-specific, and the prescriber must be a specialist or have consulted with a specialist for the condition treated.

    • Initial authorization duration: one year.
    • Reauthorization duration: two years.
    Step Therapy

    ICS/LABA Trial and Failure Required

    For severe eosinophilic asthma, the patient must try and fail one ICS/LABA inhaler within the six months before Fasenra treatment.

    • Failure means intolerance or inability to improve the condition on the required therapy after at least four weeks.

    Therapy Overview

    Fasenra (benralizumab) is an interleukin-5 (IL-5) antagonist indicated as add-on therapy for severe eosinophilic asthma. Coverage also includes treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

    Key Definitions

    Failure of ICS/LABA therapy
    FailureIntolerance to the required ICS/LABA therapy, or inability to improve the condition on that therapy
    Minimum durationAt least four weeks of required therapy when failure is based on inability to improve
    Applies toOne ICS/LABA inhaler drug tried before initial Fasenra coverage for severe eosinophilic asthma
    Non-severe EGPA
    ConditionEosinophilic granulomatosis with polyangiitis (EGPA)
    SeverityNon-severe disease
    Definition

    Initial Therapy Criteria

    Initial Severe Eosinophilic Asthma

    Initial severe eosinophilic asthma coverage requires all of the following, including one qualifying eosinophil threshold:

    Initial severe eosinophilic asthma

    • The patient has severe eosinophilic asthma requiring Fasenra as add-on therapy.
    • Supporting medical records, including prior therapies and responses to treatment, are provided.
    • ONE eosinophil threshold

      • The eosinophil level is at least 150 cells/mcL within six weeks before the immediate start of treatment with Fasenra.>= 150 cells/mcL within 6 weeks

    Reauthorization and Continuation

    Continuation Therapy

    Reauthorization requires all of the following:

    Continuation therapy for severe eosinophilic asthma or EGPA

    • Medical records supporting the reauthorization request are provided.
    • Documentation demonstrates clinical benefit from Fasenra treatment.

      Examples of clinical benefit include decreased exacerbations, improvement in symptoms, or decreased oral steroid use.

    • The reauthorization is requested for a covered indication: severe eosinophilic asthma or EGPA.Reauthorization coverage duration: two years

    Fasenra Reauthorization

    Fasenra reauthorization requires all of the following:

    Required Prior Therapy

    StepRequired therapyTime frameFailure definition
    1Try and fail one ICS/LABA inhaler drug before initial Fasenra coverage for severe eosinophilic asthmaPast six months; therapy must be attempted for at least four weeksIntolerance or inability to improve the condition on the required therapy
    Policy Summary
    PayerGold Coast Health Plan
    PolicyFasenra (benralizumab) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 21, 2025
    Last ReviewAug 21, 2025
    Next Review DateN/A
    Key ActionSubmit supporting medical records, including qualifying eosinophil levels and documented ICS/LABA trial and failure, for initial severe eosinophilic asthma requests.
    SourceLink
    On This Page
    Coverage CriteriaBilling and Clinical Coding DetailsAuthorization and Documentation RequirementsTherapy OverviewKey DefinitionsInitial Therapy CriteriaReauthorization and ContinuationRequired Prior Therapy
    Alternative qualifying eosinophil threshold for initial severe eosinophilic asthma coverage
    ICS/LABA treatment trial
    Required therapyOne ICS/LABA inhaler drug
    Treatment periodMust be tried within the past six months
    Failure conditionIntolerance or inability to improve the condition on the required therapy for at least four weeks
    Documentation Required

    Initial Severe Eosinophilic Asthma Records

    Submit medical records supporting the request, including documentation of prior therapies and the patient’s responses to treatment for severe eosinophilic asthma.

    • Document the qualifying eosinophil count: at least 150 cells/mcL within six weeks before the immediate start of Fasenra, or at least 300 cells/mcL within the previous 12 months.
    • Document the required ICS/LABA trial and failure.
    Documentation Required

    Initial EGPA Records

    For initial EGPA coverage, submit medical records supporting the request and documenting that the patient has non-severe eosinophilic granulomatosis with polyangiitis (EGPA).

    • Non-severe EGPA is defined as the absence of life-threatening or organ-threatening manifestations.
    Documentation Required

    Reauthorization Records

    Reauthorization requests for severe eosinophilic asthma or EGPA must include medical records supporting the request and documentation that the patient has experienced clinical benefit from Fasenra.

    • Examples of benefit include decreased exacerbations, improved symptoms, or decreased oral steroid use.
    Billing Rule

    Dose Documentation

    Fasenra dosing is approved according to the FDA-approved labeling or within accepted standards of medical practice.

    Denial Risk

    Concurrent Biologic Therapy

    Fasenra must not be used in combination with another biologic drug. Requests involving concurrent biologic therapy may be denied.

    • Review the patient’s medication profile and document that no other biologic is being administered concurrently.
    Prior Authorization

    Asthma Initial-Coverage Requirements

    For initial severe eosinophilic asthma coverage, submit the required medical records and verify both the qualifying eosinophil threshold and the required ICS/LABA trial and failure.

    • Eosinophils: at least 150 cells/mcL within six weeks before treatment, or at least 300 cells/mcL within the previous 12 months.
    • ICS/LABA: trial and failure within the past six months; failure requires intolerance or no improvement after at least four weeks.
    Prior Authorization

    EGPA Severity Requirement

    Initial EGPA coverage requires documentation of non-severe disease and confirmation that the patient has no life-threatening or organ-threatening manifestations.

    • Include medical records supporting the EGPA diagnosis and severity assessment.
    Documentation Required

    Clinical Benefit for Reauthorization

    For reauthorization, provide medical records documenting continued clinical benefit for severe eosinophilic asthma or EGPA.

    • Acceptable examples include fewer exacerbations, improved symptoms, or reduced oral steroid use.
    Absence of life- or organ-threatening manifestations
    Fasenra (benralizumab)
    MedicationFasenra (benralizumab)
    Drug classInterleukin-5 (IL-5) antagonist
    IndicationSevere eosinophilic asthma add-on therapy
    The eosinophil level is at least 300 cells/mcL during the previous 12 months.>= 300 cells/mcL in previous 12 months
  1. The patient tried and failed one ICS/LABA inhaler drug in the past six months.One ICS/LABA inhaler drug within the past 6 months

    Failure means intolerance or inability to improve the condition on required therapy for at least four weeks.

  2. Initial Eosinophilic Granulomatosis With Polyangiitis

    Initial EGPA coverage requires all of the following:

    Initial eosinophilic granulomatosis with polyangiitis

    • The patient is an adult with eosinophilic granulomatosis with polyangiitis (EGPA).Adult patient
    • Medical records supporting the request are provided.
    • The medical records document non-severe EGPA, defined as absence of life- or organ-threatening manifestations.Non-severe EGPA

    Fasenra reauthorization

    • Medical records supporting the request are provided.
    • Clinical benefit from Fasenra is documented for severe eosinophilic asthma or EGPA.

      Examples include decreased exacerbations, improvement in symptoms, or decreased oral steroid use.

    • The reauthorization is for a covered indication: severe eosinophilic asthma or EGPA.Reauthorization coverage duration: two years